CSL has lifted its full-year profit guidance thanks to strong sales of products, including its Seqirus flu vaccine in the northern hemisphere.
The vaccines and blood products supplier says sales of drugs to treat haemophilia and angiodema – a hereditary condition that can cause swelling of the face, abdomen and limbs – were stronger than expected and that it now expects net profit of between $US1.68 billion and $US1.71 billion on a constant currency basis.
That is as much as 28 per cent higher than the $US1.34 billion reported for the last financial year, and compares to previous guidance of $US1.55 billion to $US1.60 billion.
Chief executive and managing director Paul Perreault said the improved outlook was underpinned by “a confluence of positive outcomes”.
“Seqirus is … performing well, following a severe northern hemisphere influenza season,” Mr Perreault said.
CSL shares, which were already up about 25 per cent in the past three months, jumped on the guidance upgrade.
At 1023 AEST on Friday, they were up $8.57, or 4.9 per cent, at $184.26.